Burnaby Research, University of British Columbia, Vancouver, B.C., Canada. wendy@leong.com
This commentary briefly reviews the controversies of therapeutic and generic interchangeability, as they apply to the antithrombotic drug class called low-molecular-weight heparin (LMWH). Recommendations are prepared for the generic LMWH approval process by various regulatory bodies.